Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-South Africa, hit hard by coronavirus second wave, expects first vaccines Feb. 1

Wed, 27th Jan 2021 18:38

* South Africa worst affected country in Africa

* Fights more contagious virus variant

* AstraZeneca vaccine doses coming from India
(Adds ministry presentation, union reaction)

By Alexander Winning

JOHANNESBURG, Jan 27 (Reuters) - South Africa expects the
flight carrying its first 1 million coronavirus vaccine doses to
arrive on Feb. 1, Health Minister Zweli Mkhize said on
Wednesday, boosting efforts to curb a second wave of COVID-19
driven by a more contagious variant.

The AstraZeneca shots, produced by the Serum
Institute of India (SII), are destined for sorely stretched
healthcare workers.

South Africa has recorded the most coronavirus infections
and deaths on the African continent, at more than 1.4 million
cases and over 41,000 deaths to date. Since late last year, it
has been battling a more transmissible virus variant called
501Y.V2.

Mkhize said that after the 1 million doses arrive at the OR
Tambo international airport in Johannesburg they would be
subject to technical processes including quality assurance over
10 to 14 days.

They can then be distributed to all provinces, he added
during a public webinar. South Africa is due to receive a
further 500,000 doses from the SII in February, also for its
health workers.

Trade union NEHAWU said more doses needed to be secured
since the 1.5 million coming from the SII would only cover
750,000 health workers, as AstraZeneca's vaccine was
administered in two doses.

South Africa later stands to receive around 12 million doses
from the COVAX vaccine distribution scheme co-led by the World
Health Organization, another 12 million from an African Union
arrangement, and 9 million from Johnson & Johnson.

Mkhize spoke as South Africa's main opposition party, the
Democratic Alliance, began court action to force the government
to release details of its vaccination plans.

Some scientists and health workers have publicly criticised
the government for not securing doses sooner or outlining
detailed immunisation plans.

A health ministry presentation showed there were around 1.25
million health workers to be vaccinated, of which around 350,000
had insurance.

Vaccines would be delivered free at the point of service.
Medical schemes, funds that pool health insurance premiums,
would pay for those with insurance, with the government paying
for the uninsured.

Medicines regulator SAHPRA said earlier on Wednesday it had
given fast-track approval to AstraZeneca's vaccine for emergency
use and that it was reviewing data on the shots of rival
manufacturers Pfizer and J&J.

According to a National Treasury estimate, it could cost 20
billion to 24 billion rand ($1.3 billion to $1.6 billion) to
vaccinate the government's target of around 40 million people,
or two-thirds of the population.
(Reporting by Alexander Winning; additional reporting by
Mfuneko Toyana; Editing by Barbara Lewis, Mark Heinrich and
Grant McCool)

More News
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.